Press Releases August 27, 2026 08:00 AM

Alvotech to present at upcoming investor conferences in September

Alvotech Announces Participation in Major September Investor Conferences

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
ALVO

Alvotech, a global biotechnology company specializing in biosimilar medicines, announced that its Founder and Chairman, Robert Wessman, and Chief Strategy Officer, Dr. Balaji V. Prasad, will participate in upcoming investor conferences hosted by Morgan Stanley and Deutsche Bank in September 2026. These events include a fireside chat and investor meetings aimed at discussing the company's pipeline and strategic direction.

Alvotech to present at upcoming investor conferences in September
ALVO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Alvotech will participate in the Morgan Stanley 24th Annual Global Healthcare Conference and Deutsche Bank's 2026 Healthcare Summit, both held in New York.
  • The company's leadership will provide updates on its biosimilar products, which include approved treatments targeting autoimmune, eye disorders, and cancer.
  • Alvotech has a global commercial partnership network spanning the US, Europe, Asia, and other regions to maximize market reach for its biosimilars.

REYKJAVIK, Iceland, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Robert Wessman, Founder and Chairman, and Dr. Balaji V. Prasad, Chief Strategy Officer, will participate in the upcoming investor conferences in September as follows:

  • Morgan Stanley 24th Annual Global Healthcare Conference in New York – Fireside chat on Tuesday, September 15, 2026 at 12:20 pm ET (16:20 GMT)
  • Deutsche Bank's 2026 Healthcare Summit in New YorkHosting investor meetings on Thursday, September 17, 2026.

A live webcast of the fireside chat will be available to the general public and can be accessed in the Investors Section of Alvotech's website under Events and Presentations. After the event, a recording will be available for replay for 90 days.

For further information, contact:

Media
Benedikt Stefansson
Sarah MacLeod
[email protected]

Investors
Dr. Balaji V Prasad
Benedikt Stefansson
Mikaela Vilchez
[email protected]

About Alvotech

Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

For more information, please visit our  website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube.


Risks

  • Market adoption and regulatory approvals of biosimilar products may face challenges affecting revenue growth.
  • Competition in the biotechnology sector, specifically in biosimilars, remains intense, potentially impacting Alvotech’s market share.
  • Global economic or geopolitical uncertainties could affect investor sentiment and operational capabilities across various regions.

More from Press Releases

Correction: Entera to Participate in Upcoming Fall Investor Conferences Aug 27, 2026 Bond Announces Major Presence at Global Security Exchange 2026 in Atlanta Aug 27, 2026 HEALTHY CHOICE WELLNESS CORP.’S STOCKHOLDERS APPROVE ALL PROPOSALS IN CONNECTION WITH MERGER WITH HOST DIGITAL Aug 27, 2026 Moomoo Partners with LPGA to Launch Futu Ladies World Championship in 2027 Aug 27, 2026 Eos Energy Enterprises to Consolidate Battery Manufacturing at Thorn Hill Location Aug 27, 2026